Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia
Key claim: A phase II trial is testing whether the MEK inhibitor trametinib can control relapsed or refractory juvenile myelomonocytic leukemia by blocking enzymes required for tumor cell growth.
Abstract
This phase II trial studies how well trametinib works in treating patients with juvenile myelomonocytic leukemia that has come back (relapsed) or does not respond to treatment (refractory). Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Why this matters
JMML is a rare pediatric MDS/MPN overlap disease driven by constitutive RAS–MAPK activation, and salvage options after relapse or refractoriness to standard therapy (including HSCT) are limited. A phase II trial of trametinib in the relapsed/refractory setting complements ongoing frontline trametinib+azacitidine work, helping define whether MEK inhibition can serve across the JMML disease course. Results will shape the subtype-specific natural history of relapsed JMML and the role of targeted MAPK blockade in MDS/MPN overlap syndromes.